However, several questions remain unanswered, including if single-agent crizotinib is optimal, or if a partner of ALK fusion kinase variants influences tumor response to crizotinib (5), and if next-generation ALK inhibitors are effective post-crizotinib resistance. Here, ALK is linked to neoplasm.